	US 11,788,101 B2
	Genomic insulator elements and uses thereof
George Stamatoyannopoulos, Seattle, WA (US); and John Stamatoyannopoulos, Seattle, WA (US)
Assigned to UNIVERSITY OF WASHINGTON, Seattle, WA (US)
Filed by UNIVERSITY OF WASHINGTON, Seattle, WA (US)
Filed on Jan. 31, 2020, as Appl. No. 16/778,996.
Application 16/778,996 is a continuation of application No. 15/126,115, granted, now 10,590,433, previously published as PCT/US2015/020369, filed on Mar. 13, 2015.
Claims priority of provisional application 62/068,226, filed on Oct. 24, 2014.
Claims priority of provisional application 61/953,419, filed on Mar. 14, 2014.
Prior Publication US 2020/0263202 A1, Aug. 20, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/86 (2006.01); C12N 15/10 (2006.01); C12N 15/85 (2006.01); C12N 15/113 (2010.01); A61K 48/00 (2006.01); C12Q 1/6876 (2018.01)

CPC C12N 15/86 (2013.01) [A61K 48/005 (2013.01); C12N 15/113 (2013.01); C12Q 1/6876 (2013.01); C12N 2310/141 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/16043 (2013.01); C12N 2830/40 (2013.01)]

18 Claims

1. An expression cassette comprising a nucleic acid sequence encoding a therapeutic agent driven by a promoter regulated by an enhancer,

wherein the cassette is bracketed by genomic insulator elements,

wherein each of the genomic insulator elements comprises a CTCF binding site core sequence consisting of the nucleotide sequence set forth in SEQ ID NO:1,

wherein each of the genomic insulator elements comprises 150 to 250 nucleotides, or

wherein each of the genomic insulator elements comprises 119 to 284 nucleotides.